Clinically Proven

Postbiotics

RHT3201™

Korea's first-ever postbiotics with the human clinical test, officially approved as a dietary supplement ingredient by KFDA for its functionality. 

Oral intake of RHT3201™ showed a therapeutic effect on children with Atopic Dermatitis. 

What is Hypersensitivity Reaction?

Hypersensitivity reactions are undesirable overreactions produced by the normal immune system, such as allergies and autoimmunity.

They can occur when immune functions work excessively against a foreign substance entering the body, resulting in an immune balance breakdown.

Overall Allergy Reaction

Atopic Dermatitis

그림333.png
그림222.png

Watery Eyes

Diffculity Breathing

Under normal circumstances, the body maintains an immune balance.
When there are hypersensitivity symptoms like allergy and asthma, this means that there is an imbalance in the immune cells and that Th2 cells are working too hard, leading to a hypersensitivity reaction.*


* Development of Tyndallized Lactobacillus rhamnosus IDCC 3201 with Immunomodulation: Optimization, Validation, and in vitro Evaluation. KSBB Journal, 32(4), 271-278. 

Allergic rhinitis

이미지 제공: National Cancer Institute

The mechanism of RHT3201™

그림6123.png

The goal of RHT3201™, to maintain a balanced immunological response in human bodies, is essential as excessive immunological responses can cause hypersensitivity reactions.

 

Through several studies, RHT3201™ has shown significant effects on the production of cytokines and helps to modulate the balanced immune response between Th1 and Th2. These immunomodulatory effects lead to the suppression of hypersensitivity reactions.

이미지 제공: Ousa Chea

Clinical Study

A randomized trial of Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201™) for relieving atopic dermatitis.​

Efficacy on hypersensitivity reactions validated through SCI-indexed papers and clinical trials. Safe for humans, as shown in clinical trials for oral intake of RHT3201™ and its therapeutic effect with atopic dermatitis

Human Clinical Test Details of RHT3201™

이미지 제공: Nguyen Dang Hoang Nhu

SCORAD* Score Evaluation

*SCORing of Atopic Dermatitis(SCORAD)

The change of SCORAD total score at week 12 (primary outcome) was −13.89 ± 10.05 in the RHT3201 group (P < .0001) and −8.37 ± 9.95 in the placebo group (P < .0001) and this difference was statistically significant between the two groups (P = .0283). The SCORAD total score at week 12 in the subjects with AD for ≥50 months was reduced more profoundly by 15.34 ± 9.30 (P < .0001) in the RHT3201 group and by 7.23 ± 10.54 (P = .0367) in the placebo group (between groups, P = .0376).

rht3201.png

RHT3201™

placebo.png

Placebo

SCORAD A.png
SCORAD B.png

SCORAD total score change

SCORAD total score change

Score 12 in total subjects

Score in subjects with atopic dermatitis for over 50 months duration

SCORAD* Score Evaluation

*SCORing of Atopic Dermatitis(SCORAD)

In subgroup analysis at week 12 among subjects with AD for ≥50 months, the difference of objective SCORAD score was statistically different between groups (Figure 1). 
The difference in the reduction of the extent of disease was significantly greater in the RHT3201-treated group than in the placebo group (Figure 2).

rht3201.png

RHT3201™

placebo.png

Placebo

Scorad objective 1.png
Scorad objective 3.png
Scorad objective 2.png

SCORAD objective score change

SCORAD objective score change

-extent of disease change

SCORAD objective score change

-intensity of disease change

Change of SCORAD objective scores (objective total score, extent of disease score, and intensity of disease score) from weeks 0 to 12 in subjects with atopic dermatitis for over 50 months duration

현미경

Immunologic Analysis

By subgroup analysis at week 12 in subjects with AD for ≥50 months, the changes in ECP levels, eosinophil count, and IL-31 levels were significantly different between the two groups.
The mean ECP level was decreased by 16.76 ± 33.77 mg/dL in the RHT3201 group and was increased by 12.42 ± 21.16 mg/dL in the placebo group (Figure 1); the mean eosinophil count at week 12 was reduced by 83.53 ± 195.22 cells/μL in the RHT3201 group, whereas it was increased by 62.50 ± 155.40 cells/μL in the placebo group (Figure 2).

Furthermore, the mean IL-31 levels were decreased by 599.86 ± 985.95 pg/mL in the RHT3201 group and were increased by 330.28 ± 1038.98 pg/mL in the placebo group; this change was statistically significant between the two groups (Figure 3).

rht3201.png

RHT3201™

placebo.png

Placebo

스코랄드 1.png
스코랄드 2.png
스코랄드 3.png

ECP level change (mg/dL)

Eosinophil count change(/㎕)

IL-31 level change (pg/mL)

 

Formulating Friendly 

RHT3201™ can broaden your probiotic options.
 
RHT3201™ provides formulation flexibility of postbiotics,
with none of the stability or manufacturing concerns.
Until now, you might have only been able to rely on few applications compatible
when working with probiotic category. 
RHT3201™ is your another option in those delivery formats that require really high heat or water activity.  
 

 

Capsules

Powders

tablets

gummies

and more